Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.60 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937397 | 0.94 | F10 (0.64) | F10F2PRSS1PLGPRSS2 | |
| Trifluoroacetic Acid SCHEMBL3317848 | 0.93 | F10 (0.70) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL3313154 | 0.87 | F10 (0.53) | F10F2PRSS1PLGPRSS2 | |
| SCHEMBL11937395 | 0.87 | F10 (0.75) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL3318224 | 0.85 | F10 (0.52) | F10F2PRSS1PLGPRSS2 | |
| Trifluoroacetic Acid SCHEMBL3317771 | 0.85 | F10 (0.49) | F10F2PRSS1PLGPRSS2 | |
| Trifluoroacetic Acid SCHEMBL3315390 | 0.85 | F10 (0.49) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL3318431 | 0.83 | F10 (0.44) | F10F2PRSS1PLGPRSS2 | |
| Trifluoroacetic Acid SCHEMBL3318171 | 0.82 | F10 (0.55) | F10F2PRSS1PLGPRSS2 | |
| Trifluoroacetic Acid SCHEMBL3910305 | 0.81 | F10 (0.90) | F10F2PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1847527-A1 | NOVEL BENZAMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | F10 7/4885F2 6/4885PRSS1 92/4885 |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | F10 7/4885F2 6/4885PRSS1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.